These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 39074163)

  • 1. Understanding early HIV-1 rebound dynamics following antiretroviral therapy interruption: The importance of effector cell expansion.
    Phan T; Conway JM; Pagane N; Kreig J; Sambaturu N; Iyaniwura S; Li JZ; Ribeiro RM; Ke R; Perelson AS
    PLoS Pathog; 2024 Jul; 20(7):e1012236. PubMed ID: 39074163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding early HIV-1 rebound dynamics following antiretroviral therapy interruption: The importance of effector cell expansion.
    Phan T; Conway JM; Pagane N; Kreig J; Sambaturu N; Iyaniwura S; Li JZ; Ribeiro RM; Ke R; Perelson AS
    bioRxiv; 2024 May; ():. PubMed ID: 38746144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-Treatment Controllers: Role in HIV "Cure" Research.
    Cockerham LR; Hatano H; Deeks SG
    Curr HIV/AIDS Rep; 2016 Feb; 13(1):1-9. PubMed ID: 26781112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasticity of the Immune System in Children Following Treatment Interruption in HIV-1 Infection.
    Sandgaard KS; Margetts B; Attenborough T; Gkouleli T; Adams S; Holm M; Gibb D; Gibbons D; Giaquinto C; De Rossi A; Bamford A; Palma P; Chain B; Gkazi AS; Klein N
    Front Immunol; 2021; 12():643189. PubMed ID: 34475868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption.
    Ziani W; Shao J; Wang X; Russell-Lodrigue K; Liu YZ; Montaner LJ; Veazey RS; Xu H
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33408173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
    Aamer HA; McClure J; Ko D; Maenza J; Collier AC; Coombs RW; Mullins JI; Frenkel LM
    PLoS Pathog; 2020 Aug; 16(8):e1008791. PubMed ID: 32841299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological remission after antiretroviral therapy interruption in female African HIV seroconverters.
    Gossez M; Martin GE; Pace M; Ramjee G; Premraj A; Kaleebu P; Rees H; Inshaw J; Stöhr W; Meyerowitz J; Hopkins E; Jones M; Hurst J; Porter K; Babiker A; Fidler S; Frater J;
    AIDS; 2019 Feb; 33(2):185-197. PubMed ID: 30325764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption.
    Giron LB; Papasavvas E; Yin X; Goldman AR; Tang HY; Palmer CS; Landay AL; Li JZ; Koethe JR; Mounzer K; Kostman JR; Liu Q; Montaner LJ; Abdel-Mohsen M
    mBio; 2021 Feb; 12(1):. PubMed ID: 33622719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption.
    Papasavvas E; Kostman JR; Thiel B; Pistilli M; Mackiewicz A; Foulkes A; Gross R; Jordan KA; Nixon DF; Grant R; Poulin JF; McCune JM; Mounzer K; Montaner LJ
    J Clin Immunol; 2006 Jan; 26(1):40-54. PubMed ID: 16418802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers.
    Rosás-Umbert M; Llano A; Bellido R; Olvera A; Ruiz-Riol M; Rocafort M; Fernández MA; Cobarsi P; Crespo M; Dorrell L; Del Romero J; Alcami J; Paredes R; Brander C; Mothe B
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients.
    Van Gulck E; Bracke L; Heyndrickx L; Coppens S; Atkinson D; Merlin C; Pasternak A; Florence E; Vanham G
    PLoS One; 2012; 7(5):e37792. PubMed ID: 22666392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discordance between HIV-1 Population in Plasma at Rebound after Structured Treatment Interruption and Archived Provirus Population in Peripheral Blood Mononuclear Cells.
    Hendricks CM; Cash MN; Tagliamonte MS; Riva A; Brander C; Llano A; Salemi M; Stevenson M; Mavian C
    Microbiol Spectr; 2022 Aug; 10(4):e0135322. PubMed ID: 35699458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
    García F; Plana M; Vidal C; Cruceta A; O'Brien WA; Pantaleo G; Pumarola T; Gallart T; Miró JM; Gatell JM
    AIDS; 1999 Jul; 13(11):F79-86. PubMed ID: 10449278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral Decay Dynamics and Mathematical Modeling of Treatment Response: Evidence of Lower in vivo Fitness of HIV-1 Subtype C.
    Shet A; Nagaraja P; Dixit NM
    J Acquir Immune Defic Syndr; 2016 Nov; 73(3):245-251. PubMed ID: 27273158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling the time course of CD4 T-lymphocyte counts according to the level of virologic rebound in HIV-1-infected patients on highly active antiretroviral therapy.
    Kousignian I; Abgrall S; Duval X; Descamps D; Matheron S; Costagliola D;
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):50-7. PubMed ID: 14501793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
    Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
    AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus.
    Thompson M; Heath SL; Sweeton B; Williams K; Cunningham P; Keele BF; Sen S; Palmer BE; Chomont N; Xu Y; Basu R; Hellerstein MS; Kwa S; Robinson HL
    PLoS One; 2016; 11(10):e0163164. PubMed ID: 27711228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.
    Clarridge KE; Blazkova J; Einkauf K; Petrone M; Refsland EW; Justement JS; Shi V; Huiting ED; Seamon CA; Lee GQ; Yu XG; Moir S; Sneller MC; Lichterfeld M; Chun TW
    PLoS Pathog; 2018 Jan; 14(1):e1006792. PubMed ID: 29324842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.